Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260087 · ClinicalTrials.gov registry record
New Daily Persistent Headache Biomarkers Study
A clinical trial, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04260087: Clinical Trial study, sponsored by Albert Einstein College of Medicine.
NCT04260087 is a clinical trial that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04260087 was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder. The goal of this study is to evaluate the blood levels of two proteins involved with pain signaling; calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF). CGRP levels are known to be elevated in chronic migraine, and recent phase 2 clinical trials suggest that treatments targeting CGRP are safe and effective for treatments for migraine. If CGRP levels are elevated in the blood of people with new daily persistent headache, future studies will be designed to evaluate whether treatments that target CGRP are effective in treating new daily persistent headache. If NGF levels are elevated in the blood of patients with new daily persistent headache and/or chronic migraine, future studies will be designed to evaluate whether treatments that target NGF antibodies (targeted treatments against NGF) are effective in treating NDPH and/or chronic migraine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2021-11-18 |
Why NCT04260087 stopped before completion
NCT04260087 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04260087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04260087 about?
NCT04260087 is a clinical study titled "New Daily Persistent Headache Biomarkers Study". New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder. The goal of this study is to evaluate the blood levels of two proteins involved with pain sign...
What is the current status of trial NCT04260087?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2018-05-01. Estimated completion is 2021-11-18.
Who is sponsoring clinical trial NCT04260087?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI